scholarly journals STUDY THE PREVALENCE OF MALNUTRITION AMONG CRHON'S DISEASE PATIENTS DURING CLINICAL REMISSION

2020 ◽  
Vol 3 (1) ◽  
pp. 1-12
Author(s):  
Safia S. Elramli
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Personal Information ◽  
Medical Center ◽  
Normal Range ◽  
Skin Fold Thickness ◽  
Skin Fold ◽  
Strict Diet ◽  
24 Hour Recall ◽  
The Relationship

Purpose: People with Crohn's disease are at risk of nutritional deficiency, especially those subject to strict diet. Aim of this study is to study the relationship between malnutrition and Crohn's disease during clinical remission.Methods: The patients were randomized from the Benghazi Medical Center. The total of the patients was 50 patients with 26 males and 24 females aged from 18 years and over was performed between the January 2017 to April 2017.   Self-administered questionnaire was used to collect personal information. The questionnaire included socio-economic characteristics, anthropometry, 24hr.recall method to find out whether they are malnourished or not.Result: approximately 82% of patients had their weight within the normal range, while 8% of their weight was below the normal range among of them approximately 6%   represented with men according to the BMI. As for skin fold thickness, it appeared that 36% of patients have ideal fat levels, 26% have lower fat levels, while ,22% have medium fat levels, whereas the rest (14%) have higher fat levels. Regarding the 24-hour recall method shows that most patients had their daily calories at a low rate and the maximum daily calorie consumption was 1115Kcal , while the minimum was 305Kcal.Conclusion: We conclude that the relationship between Crohn's disease and malnutrition is does not exist based on our study. Our study may lack some laboratory investigations of patients. Future studies will be needed to document the relation between malnutrition and Crohn's disease.

scholarly journals Short-term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn’s disease: a retrospective study

2021 ◽  
Vol 14 ◽  
pp. 175628482110430
Author(s):  
Hee Seung Hong ◽  
Kyuwon Kim ◽  
Kyunghwan Oh ◽  
Jae Yong Lee ◽  
Seung Wook Hong ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Oral Administration ◽  
Clinical Response ◽  
Activity Index ◽  
Medical Center ◽  
Retrospective Chart Review ◽  
Asian Population ◽  
Aminosalicylic Acid ◽  
Parenteral Injection

Introduction: Immunomodulators remain fundamental for the medical treatment of Crohn’s disease (CD). Methotrexate (MTX) is widely used as a second-line immunomodulator; however, there is a lack of recent data on MTX monotherapy among the Asian population with CD. Therefore, in this study, we aimed to investigate the tolerability and clinical outcomes of MTX in Korean patients with CD. Methods: A retrospective chart review was performed for CD patients treated with MTX monotherapy or in combination with 5-aminosalicylic acid (5-ASA), at the Asan Medical Center, Seoul, South Korea. The tolerability of MTX monotherapy within 6 months was assessed and the clinical effectiveness of MTX was evaluated based on the Crohn’s disease activity index (CDAI). Results: In total, 85 patients were included, of which 29 (34.1%) discontinued MTX due to intolerability during the follow-up. Adverse events (AEs) were reported in 41 (48.2%) patients. The most common AE was gastrointestinal disorders (17/41) and only one patient experienced a serious AE, a systemic infection that required hospitalization. Among the 56 patients who tolerated MTX within 6 months, 44 (65.9%) showed a clinical response. Moreover, no factor was significantly associated with intolerability. The administration method was the only factor significantly associated with a response to MTX ( p = 0.041). The adjusted odds ratio of parenteral injection compared to oral administration was 5.68 (95% confidence interval (CI), 1.07–30.08). Conclusion: In this study, one-third of patients were intolerant to MTX; nonetheless, the response rate was as high as 65.9% among tolerant patients. In addition, no significant factors affected intolerability. In terms of the clinical response, parenteral injection could be better than oral administration.

SKIN-FOLD THICKNESS IN NORMAL SUBJECTS AND IN PATIENTS WITH ACROMEGALY AND CUSHING'S SYNDROME

1969 ◽  
Vol 60 (4) ◽  
pp. 705-711 ◽  
Author(s):  
A. D. Wright ◽  
G. F. Joplin
Keyword(s):  
Cushing’S Syndrome ◽  
Normal Subjects ◽  
Cushing's Syndrome ◽  
Normal Range ◽  
Clinical Method ◽  
Skin Fold Thickness ◽  
Skin Fold ◽  
Normal Mean ◽  
The Mean ◽  
Age And Sex

ABSTRACT A simple clinical method of determining the skin-fold thickness on the dorsum of the hand has been described using the Harpendon spring-loaded caliper. A normal range for age and sex has been established in 258 normal subjects. The mean skin-fold thickness was greater in men than in women, and in both decreased with age, falling from 2.85 to 1.75 mm in men, and from 2.65 to 1.60 mm in women (aged 15–20 to 70–80). In 48 acromegalic patients, 71 % of the skin-fold measurements were abnormally thick. In 12 patients with Cushing's syndrome, although all measurements were below the normal mean, 42 % only were abnormally thin.

P108 TEDUGLUTIDE USE IN CROHN’S DISEASE: A CASE SERIES

2020 ◽  
Vol 26 (Supplement_1) ◽  
pp. S23-S23
Author(s):  
Adeeti Chiplunker ◽  
Christina Ha ◽  
Shirley Paski
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Median Duration ◽  
Dose Adjustment ◽  
Medical Center ◽  
Case Series ◽  
Dose Interval ◽  
Retrospective Case ◽  
Inflammatory Bowel

Abstract Background Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue with trophic effects on the intestinal mucosa to increase the absorptive surface area and enhance nutrient and fluid absorption of the small bowel (SB).1 It has been shown to reduce parenteral nutrition (PN) and intravenous fluid (IVF) requirements and is an important adjunct in the medical management of short bowel syndrome (SBS).1–2 Crohn’s disease (CD) is an important etiology of SBS but use of teduglutide in this population can be challenging. Aim The aim of this case series was to describe the use of teduglutide in CD patients. Methods A retrospective case series of all CD patients with SBS who used teduglutide at the Inflammatory Bowel Disease Center at Cedars-Sinai Medical Center. Age, duration of SBS, length of remaining SB and colonic continuity status were recorded. BMI, average daily PN kilocalories (kcal), and IVF requirements were recorded at the time of teduglutide initiation. The duration of teduglutide use was calculated. Teduglutide dose, dose adjustment history, reason for dose adjustment, and therapy complications were noted. Results 9 patients were included (5 male/4 female). Median age was 57 years (IQR 32). Median length of remaining small bowel was 60cm (IQR 27.5) and median duration of SBS was 8 years (IQR 9.83). Median BMI at teduglutide initiation was 18.66 (IQR 4.29) with a median duration of PN of 4.5 years (IQR 9.42) and median PN kcal/day of 971.43 (IQR 518). The median duration of teduglutide was 1.1 years (IQR 3.4). 4 patients (44%) had a teduglutide dose change. 2 patients had dose interval extended from daily to every other day to reduce injection burden. 1 patient developed obstructive symptoms on daily dosing, which resolved when the dose interval was extended to every other day. 1 patient had to stop therapy due to a small bowel obstruction requiring hospitalization. 8 patients (88%) were able to wean or stop PN/IVF with addition of teduglutide. 1 patient had to restart PN despite teduglutide therapy. Table 1. Discussion Teduglutide is effective in Crohn’s disease patients and facilitates weaning of PN and IVF requirements. Most patients tolerate the recommended dose with daily injections, but the dose interval can be extended to every other day to reduce obstructive symptoms or reduce the injection burden without affecting ability to wean PN/IVF. References

scholarly journals Biologics and surgical outcomes in Crohn’s disease: is there a direct relationship?

2020 ◽  
Vol 13 ◽  
pp. 175628482093173
Author(s):  
Abel Botelho Quaresma ◽  
Takayuki Yamamoto ◽  
Paulo Gustavo Kotze
Keyword(s):  
Crohn’S Disease ◽  
Postoperative Complications ◽  
Crohn's Disease ◽  
Direct Relationship ◽  
Significant Proportion ◽  
Perioperative Period ◽  
Prospective Data ◽  
Treatment Algorithms ◽  
The Relationship ◽  
Necrosis Factor

Despite significant advances in medical therapy in the management of Crohn’s disease (CD), surgery is still required in a significant proportion of patients and constitutes an important tool in treatment algorithms. Recently, more options of biological agents have been made available, and most patients with CD undergoing surgical procedures have been previously exposed to this class of drugs. There is controversy in the literature as to whether anti-tumor necrosis factor (TNF) agents, anti-integrins, or anti-interleukins (ILs) have a direct relationship with increased postoperative complications. In this narrative review, the authors summarize the most important data regarding the effect of biologics on postoperative outcomes in CD. Most studies (with different designs) are based on the experience with anti-TNF agents, mostly with infliximab. Some studies outlined the relationship between vedolizumab and postoperative complications, and there is a lack of data with ustekinumab in this scenario. Most studies are retrospective, but few prospective data are available. A cause–effect (proof of concept) direct relationship between biologics and an increase in postoperative morbidity has not been demonstrated to date. Several confounding factors such as previous use of steroids, malnutrition, and unfavorable abdominal conditions have a definitely effect on postoperative complications in CD. Biologics seem safe to be used in the perioperative period, but available data are still controversial. Multidisciplinary individualized decisions should be made on a case-to-case basis, adapting the surgical strategy according to risk factors involved.

scholarly journals IRGMGene Variants Modify the Relationship Between Visceral Adipose Tissue and NAFLD in Patients With Crohn’s Disease

2018 ◽  
Vol 24 (10) ◽  
pp. 2247-2257 ◽  
Author(s):  
Tracey G Simon ◽  
Kimberley W J Van Der Sloot ◽  
Samantha B Chin ◽  
Amit D Joshi ◽  
Paul Lochhead ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Visceral Adipose Tissue ◽  
Visceral Adipose ◽  
The Relationship

S1205 Stability of Granuloma Formation Over Time in Patients with Crohn's Disease and the Relationship with Variants in Autophagy Genes

2009 ◽  
Vol 136 (5) ◽  
pp. A-212-A-213
Author(s):  
Marko Brinar ◽  
Gert D. Hertogh ◽  
Isabelle Cleynen ◽  
Liesbet Henckaerts ◽  
Gert A. Van Assche ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Granuloma Formation ◽  
The Relationship ◽  
Over Time

scholarly journals CNTNAP3 Associated ATG16L1 Expression and Crohn’s Disease

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Yu Qi Qiao ◽  
Mei Lan Huang ◽  
Qing Zheng ◽  
Tian Rong Wang ◽  
An Tao Xu ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Gene Mutations ◽  
In Vitro Study ◽  
Reactive Protein ◽  
Signaling Axis ◽  
Nucleotide Oligomerization ◽  
The Relationship ◽  
Normal Controls

Autophagy is a common physiological process in cell homeostasis and regulation. Autophagy-related gene mutations and autophagy disorders are important in Crohn’s disease (CD). The nucleotide oligomerization domain 2–autophagy genes autophagy 16-like 1 (NOD2–ATG16L1) signaling axis disorder contributes to the dysfunction of autophagy. This paper is focused on the relationship between contactin associated protein-like 3 (CNTNAP3) and ATG16L1 expression in Crohn’s disease. The results indicated that the expression of ATG16L1 is higher in some CD patients compared to normal controls. ATG16L1 was well correlated with the C-reactive protein (CRP) in some CD patients. In vitro study revealed that CNTNAP3 could upregulate the expression of ATG16L1 and increase autophagy vacuoles.

scholarly journals Herb-Partitioned Moxibustion and the miRNAs Related to Crohn’s Disease: A Study Based on Rat Models

2015 ◽  
Vol 2015 ◽  
pp. 1-13 ◽  
Author(s):  
Kai Wei ◽  
Dan Zhang ◽  
Jue Hong ◽  
Cuihong Zhang ◽  
Xiaoming Feng ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Target Genes ◽  
Inflammatory Responses ◽  
Signal Pathways ◽  
Rat Models ◽  
Inflammatory Bowel ◽  
Experimental Researches ◽  
The Relationship

Crohn’s disease (CD) is a major subtype of inflammatory bowel disease (IBD). Herb-partitioned moxibustion (HPM) has been proven to be effective in treating CD by a large amount of clinical and experimental researches. MiRNAs (microRNAs) are increasingly recognized as important posttranscriptional regulators of inflammatory genes. In this study, we established experimental CD rat models and investigated the miRNAs associated with the onset of experimental CD; then, we further identified CD-related miRNAs that were regulated by HPM and explored the relationship between CD and the potential target genes of involved miRNAs. We found that miR-147 and miR-205 were significantly downregulated in colons of experimental CD rats and may be closely associated with the onset of experimental CD. HPM may extenuate inflammatory responses in colons and ameliorate colonic damages in CD via upregulating the expression of miR-147 and miR-205 and then further downregulating the expression of inflammation-related mRNAs, negatively regulating inflammatory signal pathways, and reducing the production of downstream inflammatory cytokines.

A meta-analysis of the relationship between MYO9B gene polymorphisms and susceptibility to Crohn’s disease and ulcerative colitis

2016 ◽  
Vol 77 (10) ◽  
pp. 990-996 ◽  
Author(s):  
Peng Li ◽  
Xiao-Ke Yang ◽  
Xiu Wang ◽  
Meng-Qin Zhao ◽  
Chao Zhang ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Gene Polymorphisms ◽  
Meta Analysis ◽  
The Relationship
Sign in / Sign up

Export Citation Format

Share Document